Abstract
The EarlyCDT-Lung test detects autoantibodies to abnormal cell surface proteins in lung cancer patients. It has been studied in UK1 and USA2 in diagnosing lung cancer patients and has a sensitivity of up to 47%, specificity up to 90% and positive predictive value of 16%. It is a potential diagnostic test and when combines with radiological (Computed Tomography) test, the positive predictive value can be enhanced up to 72%3. We want to study the performance of the test in a predominantly Asian ethnic city. 1. Caroline J. Chapman et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumor Biol. 2012; 33:1319–1326 2. JR Jett et al. Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: An evaluation of its performance in routine clinical practice. Lung Cancer 2014; 83:51–55 . 3. P Massion et al. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer Journal of Thoracic Oncology 2017; 12:578-584
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
